• Clinical Insights: June 23, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Bevyxxa™ (betrixaban) – June 23, 2017 – The U.S. Food and Drug Administration approved betrixaban (Bevyxxa™, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients… Read more »